NeuroMed

Company Overview

Snapshot

Founded in January 2005, NeuroMed operates with 1–10 employees. The company has raised $1M across one funding round. NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

Business overview

NeuroMed Pharmaceuticals specializes in developing treatments for neurological degenerative diseases, with a core focus on Yac-101, a compound designed to address neuro-degeneration. Yac-101 utilizes specific metal chelation to prevent reactive oxygen species, maintain cytosolic calcium homeostasis, preserve mitochondrial function, and protect against cell membrane damage. The company operates within the pharmaceuticals sector, targeting the United States market with its therapeutics and cell therapy solutions.

Strategic signal

In October 2015, the U.S. arm of Sun Pharma's Taro acquired Zalicus Pharmaceuticals, which had previously integrated NeuroMed. This acquisition highlights the ongoing consolidation and strategic realignments within the pharmaceutical industry, particularly concerning companies focused on specialized drug development and biosimilars. For investors, this signals a dynamic M&A landscape where smaller, innovative biopharma assets are being absorbed by larger players seeking to expand their portfolios in areas like pain management and biosimilar drugs.

Company Intelligence Q&A

What is NeuroMed's primary focus?

NeuroMed Pharmaceuticals focuses on developing treatments for neurological degenerative diseases, with its lead product candidate, Yac-101, targeting neuro-degeneration.

When was NeuroMed acquired?

NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

What is Yac-101?

Yac-101 is a potential treatment for injuries involving neuro-degeneration, based on specific metal chelation to prevent reactive oxygen species and maintain cellular function.

What was the subsequent acquisition involving NeuroMed's acquirer?

In October 2015, the U.S. arm of Taro Pharmaceuticals acquired Zalicus Pharmaceuticals, which had previously integrated NeuroMed.

What is the employee count for NeuroMed?

NeuroMed operates with 1–10 employees.